Cost-effectiveness of Brentuximab Vedotin plus chemotherapy as frontline treatment of systemic anaplastic large cell lymphoma in Italy

Objective: Systemic anaplastic large cell lymphoma (sALCL) is a rare and severe non-Hodgkin lymphoma. Despite its clinical relevance, the aetiology of this disease is unknown, not allowing the patient to prevent and counteract it. This study investigates the cost-effectiveness of Brentuximab Vedoti...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrea Marcellusi, Chiara Bini, Laura Fioravanti, Silvia Ripoli, Paolo Morelli
Format: Article
Language:English
Published: AboutScience Srl 2025-04-01
Series:Global & Regional Health Technology Assessment
Subjects:
Online Access:https://journals.aboutscience.eu/index.php/grhta/article/view/3306
Tags: Add Tag
No Tags, Be the first to tag this record!